Transmission of Creutzfeldt-Jakob disease (CJD) from cadaveric growth hormone injections had previously been reported in 7 cases, including one from Britain. As a result, the treatment was abandoned in 1985 and superceded by safer recombinant DNA growth hormone injections. Recent reports now record the number of cases worldwide as 23, but with the incubation period being measured in years, new cases of CJD can still present. We give a detailed report of one of the recent cluster of British cases and aim to highlight the problem to clinicians who may encounter further patients with cadaveric growth hormone induced CJD. He presented in February 1990 with a 6 month history of vague personality changes when he was noted to be somewhat surly and less efficient at his job as a bank clerk. There had then been a rapid decline with a 3 month history of progressive gait ataxia, limb incoordination and slurred speech. Following presentation he developed spontaneous limb myoclonus, became withdrawn, bedbound and then doubly incontinent over the 2 weeks before admission to hospital.
latrogenic transmission of CJD from cadaveric growth hormone had been reported in 7 patients, including one British case ' and it had been hoped that the epidemic was over. 2 The earlier Raben and Wilhelmi preparation methods for growth hormone had been discontinued' and replaced by highly purified forms4 thought unlikely to contain the infective agent. 5 In turn, these preparations were also withdrawn and replaced by recombinant DNA produced growth hormone; Britain At that stage his general examination was normal. In the neurological examination spontaneous myoclonic jerks were seen in all 4 limbs and he had a marked startle response to loud noises. Bilaterally there were hand and foot primitive grasp reflexes. He was withdrawn but initially orientated in time and place; his speech demonstrated cerebellar dysarthria. In the cranial nerves, he was blind in the right eye, the left could only perceive light.
He had bilateral optic atrophy with pupils of equal size. The left eye reacted directly and the right eye consensually to light; accommodation could not be determined. The rest of the cranial nerves were intact. In his limbs there was normal tone and power. There were brisk left arm reflexes but reflexes were normal in the right arm and legs, with flexor plantar responses. There was severe cerebellar ataxia in his limbs and trunk; he could not walk or sit up in bed. The sensory system was normal except for mild bilateral proprioceptive loss in his feet. 19 In 1959 the first clinical use of human growth hormone was described and there were 1908 people in Britain and approximately 10 000 people in the USA who had received growth hormone treatment.7 "The number of pituitary glands used to produce a batch of growth hormone was up to 20 000, with remnants of one batch sometimes being retained and added to future batches;2`0 thus there was the potential to infect many growth hormone vials from only one infected gland.
The human growth hormone preparations used fall broadly into 2 categories.3 Before 1975, treatment was almost entirely with growth hormone prepared by the methods of Raben'5 or Wilhelmi, which was later modified."' Acetone-dried powdered pituitary tissue was subjected to repeated organic solvent extractions (Raben) or alkali and acid precipitations (Wilhelmi). With these methods, the product contained impurities of a much higher molecular weight than growth hormone.3 After 1975, the method of extraction was substantially modified using frozen glands and a more gentle extraction procedure incorporating isoelectric precipitation and 2 chromatographic steps.4 "' These modifications were expected to remove the CJD infective agent from the product.3 An extensive study of this advanced "Lowry" purification procedure concluded that there was a very low risk that the final product would contain any infective agent.5
In primates, direct intracerebral inoculation of the CJD infective agent causes a greater than 90% disease spread even with small amounts of the agent, but when a small dose is administered by the subcutaneous or intra-muscular routes, transmission is irregular and when it does occur is usually followed by extremely long incubation periods.2 It is therefore likely that transmission in hypopituitary patients using low concentrations of the CJD infective agent with a peripheral route will infect only limited numbers.2 However, the minimum incubation periods in the alreadyidentified patients have ranged from 8 to 28 years," suggesting that even more cases may be found. Recent work indicates that these patients may have an increased susceptibility to acquire cadaveric growth hormone induced CJD on the basis of their genotype,'9 an exciting possibility which may be relevant to other transmissible degenerative encephalopathies. This is the first detailed report of a case of cadaveric growth hormone induced CJD since December 1986, when it was hoped that the "microepidemic" was over.2 Over a period of 11 years our patient received both the "Wilhelmi" and the newer "Lowry" type human growth hormone, before receiving recombinant DNA injections, but it remains unclear as to when he was infected. The previous neurosurgery is very unlikely to be the cause, as previous transmissions by this route had much shorter incubation periods of less than 2 years. l Our report raises the possibility that further cases of this unpleasant condition may still occur.
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